Jump to content

PubMed RSS Feed - -A Randomized-Controlled Trial of Oral Low-Dose Isotretinoin for Difficult-To-Treat Papulopustular Rosacea.


rss

Recommended Posts

A Randomized-Controlled Trial of Oral Low-Dose Isotretinoin for Difficult-To-Treat Papulopustular Rosacea.

J Invest Dermatol. 2016 Feb 5;

Authors: Sbidian E, Vicaut É, Chidiack H, Anselin E, Cribier B, Dréno B, Chosidow O

Abstract
Rosacea is a chronic inflammatory facial skin disease with psychosocial impact. Oral cyclines are recommended for moderate-to-severe papulopustular rosacea. Oral isotretinoin was found valuable for difficult-to-treat cases in several reports. This multicenter, double-blind, randomized-placebo-controlled trial compared oral isotretinoin (0.25 mg/kg/day) to placebo (2:1 ratio) for difficult-to-treat papulopustular rosacea. Included patients had at least 8 papulopustular lesions. The primary endpoint after the 4-month-treatment period was the response rate: at least 90% reduction of the number of papules/pustules compared to baseline. Secondary outcomes included measures on quality of life (Skindex score). Between February 2007 and August 2009, 156 patients were randomized to receive either isotretinoin (n=108) or placebo (n=48). In the intention-to-treat population, 57.4% of isotretinoin recipients reached the primary endpoint, compared to 10.4% of those taking the placebo (absolute difference, 47 percentage points; 95% confidence interval (CI), 34.3-59.7; P<0.0001). To consider therapy successful, 2.1 (95% CI 1.7-2.9) patients had to be treated. Skindex scores had improved significantly more for isotretinoin- than placebo-treated patients. Rosacea relapsed in 27 (58.3%) out of 51 patients who accepted 4 months of continued follow-up, with a median of 15 weeks to recurrence. The percentages of patients in each arm who stopped their treatment because of adverse event(s) did not differ. Low-dose isotretinoin was an effective therapeutic option for difficult-to-treat papulopustular rosacea. Further studies should investigate the value of a minimal effective isotretinoin dose to maintain these remissions.

PMID: 26854486 [PubMed - as supplied by publisher]

{url} = URL to article

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...